PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Webcasts


Play New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations
Erik Stroes New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations
Play Inclisiran: The Phase 3 trial
Frederick J. Raal Inclisiran: The Phase 3 trial
Play FOURIER trial: Update on subgroup analyses
Peter Sever FOURIER trial: Update on subgroup analyses
Play ODYSSEY OUTCOMES: Update
Andreas M Zeiher ODYSSEY OUTCOMES: Update
Play The new AHA/ACC Treatment Guidelines: Critical appraisal
Henry Ginsberg The new AHA/ACC Treatment Guidelines: Critical appraisal
Play Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?
Børge Nordestgaard Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?
Play ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)
Gregory G. Schwartz Michael Szarek ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)
Play Lp(a) and CV risk: Insights from the FOURIER trial
Erin Bohula Lp(a) and CV risk: Insights from the FOURIER trial
Play Genetics of Lp(a) and CVD
Anne Tybjaerg-Hansen Genetics of Lp(a) and CVD
Play Do LDL subfractions matter?
John Chapman Do LDL subfractions matter?
Play PCSK9 and the adrenals: how are cholesterol levels protected?
Bo Angelin PCSK9 and the adrenals: how are cholesterol levels protected?
Play Does one plaque characteristic fit all?
Gerard Pasterkamp Does one plaque characteristic fit all?
Play Lp(a) as a cardiovascular risk factor – Is lowering Lp(a) beneficial when LDL is low?
Pia Kamstrup Lp(a) as a cardiovascular risk factor – Is lowering Lp(a) beneficial when LDL is low?
Play Low LDL-C and cognitive function: Benefit or harm?
Francois Mach Low LDL-C and cognitive function: Benefit or harm?
Play Do low LDL-C levels enhance diabetes risk?
Dirk Müller-Wieland Do low LDL-C levels enhance diabetes risk?
Play Do low LDL-C levels achieved with statin therapy increase the risk for diabetes mellitus?
Henry Ginsberg Do low LDL-C levels achieved with statin therapy increase the risk for diabetes mellitus?
Play ODESSEY OUTCOMES Trial: Topline results
J Wouter Jukema ODESSEY OUTCOMES Trial: Topline results
Play Inclisiran and the ORION Project
Frederick J. Raal Inclisiran and the ORION Project
Play FOURIER: Timing is everything
Gaetano De Ferrari FOURIER: Timing is everything
Play An update on cardiovascular disease, depression and adherence
David Hare An update on cardiovascular disease, depression and adherence

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved